KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Capital Expenditures (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Capital Expenditures for 16 consecutive years, with $127444.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $127444.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285698.0 through Dec 2025, down 41.44% year-over-year, with the annual reading at $285698.0 for FY2025, 41.44% down from the prior year.
  • Capital Expenditures hit $127444.0 in Q4 2025 for Inovio Pharmaceuticals, up from $91564.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $736399.0 in Q3 2022 to a low of -$695863.0 in Q4 2022.
  • Historically, Capital Expenditures has averaged $93828.3 across 5 years, with a median of $127444.0 in 2025.
  • Biggest YoY gain for Capital Expenditures was 484.31% in 2021; the steepest drop was 1853.07% in 2021.
  • Year by year, Capital Expenditures stood at $175735.0 in 2021, then plummeted by 495.97% to -$695863.0 in 2022, then soared by 103.44% to $23915.0 in 2023, then soared by 87.56% to $44856.0 in 2024, then skyrocketed by 184.12% to $127444.0 in 2025.
  • Business Quant data shows Capital Expenditures for INO at $127444.0 in Q4 2025, $91564.0 in Q3 2025, and $66690.0 in Q2 2025.